Clonal, noniridescent mutants ofActinobaciUlus pleuropneumoniae serotypes 1 and 5 were isolated following chemical mutagenesis with ethyl methanesulfonate. The absence of any detectable capsule was confirmed by inhibition radioimmunoassay. There were no differences between the parent and mutant strains in lipopolysaccharide or protein electrophoretic profiles or in hemolytic activity. There was no detectable reversion to the encapsulated phenotype in vitro after passage in mice or pigs or in microporous capsules that were implanted subcutaneously in pigs for 6 weeks. The mutants were able to survive for more than 1 week in pigs following subcutaneous inoculation, which resulted in a strong immune response to whole cells and Apx toxins I and II. Intratracheal challenge of pigs with the serotype 5 mutant at a dose 1 log greater than the 50% lethal dose for the parent resulted in no clinical disease or lesions except in one pig that had slight pneumonia and pleuritis.
Actinobacillus (Haemophilus) pleuropneumoniae is the etiologic agent of porcine pleuropneumonia, which is responsible for large economic losses worldwide in the swine industry. Swine infected with A. pleuropneumoniae may be asymptomatic or may present with chronic to acute disease. Acute disease in a nonimmune herd is often associated with high mortality. In contrast, chronic disease may be less obvious but still responsible for substantial economic losses due to poor weight gain and failure to thrive. Introduction of asymptomatic carriers into a nonimmune herd is an important cause of pleuropneumonia outbreaks (22) . Acute pleuropneumonia is characterized by fibrinous adhesions in the pleural cavity and necrotic and hemorrhagic lesions in the lungs (19) . Chronic lesions involve considerable fibrosis and purulent inflammation, while asymptomatic infections have few gross lesions other than convalescent chronic lesions (i.e., fibrosis with pleural adhesions).
The bacterial factors that are responsible for virulence in A. pleuropneumoniae include capsular polysaccharide, lipopolysaccharide (LPS) or endotoxin, and the hemolytic and cytotoxic RTX (Apx) toxins (6) . Heat-labile Apx toxins are thought to be particularly important in the development of severe lesions and for induction of protective immunity in animals; nonhemolytic mutants are avirulent and cannot induce protective immunity in animals (11) . In addition, commercial vaccines consisting of killed bacteria that lack the Apx toxins do not provide adequate protection (5, 16, 18) . Protection by antibody to capsule or LPS is also inadequate, but the capsule is a required virulence factor and prevents opsonization and clearance of bacteria in the lung by the host (8) . Optimal protection of pigs against infection * Corresponding author.
by homologous and heterologous serotypes seems to occur following natural infection with A. pleuropneumoniae (17) . Our objective was to develop live, stable, attenuated strains ofA. pleuropneumoniae that would be safe to use in nonimmune pigs, would provide improved protection against clinical disease and development of lesions, and would be practical for commercial development.
MATERLILS AND METHODS
Bacterial strains and mutagenesis. The bacterial strains used in this study were A. pleuropneumoniae J45 serotype 5, A. pleuropneumoniae 4074 serotype 1, and the noncapsulated mutants of these strains. The source of the parent strains and growth conditions have been described previously (9) . Bacteria were treated with ethyl methanesulfonic acid by modification of a procedure described by Murchison et al. (15) . Briefly, bacteria in brain heart infusion broth containing NAD (BHI-N) were grown to mid-log phase, 0.015 ml of ethyl methanesulfonic acid per ml of culture was added, and the bacteria were incubated for an additional 3 h. The bacteria were then washed in 0.01 M phosphate-buffered saline (PBS), pH 7.4, and resuspended in BHI-N. Undiluted and diluted suspensions of the mutagenized bacteria were spread on BHI-N plates and incubated at 37°C for 24 to 48 h. Clonal isolates of noniridescent colonies that were confirmed to beA. pleuropneumoniae (by hemolytic activity and failure to grow on blood agar) were obtained in pure culture and further characterized.
Phenotypic characterization and stability. Total capsule content was determined by inhibition radioimmunoassay of mid-log-phase bacterial cultures (including bacteria and medium) as described elsewhere (7) . Electrophoretic profiles of LPS (one dimension) and total proteins (one and two dimen-NONCAPSULATED A. PLEUROPNEUMONIAE LIVE VACCINES sions) were evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by silver staining (11) or immunoblotting (13) . Hemolytic activity was determined by a quantitative hemolysis assay using rabbit erythrocytes (14) . Quantitative determination of Apx toxin II from culture supernatants of strains J45 and 4074 and their noncapsulated mutants was accomplished by immunoblotting of culture supernatants with monoclonal antibody 8C2 specific for Apx toxin II (14) .
To determine the stability of the noncapsulated phenotype in vitro, strain J45-C was grown to 109 CFU/ml (determined spectrophotometrically), and 1 ml was centrifuged at 10,000
x g for 15 min, suspended in 25 RI of PBS, and tested for extracellular capsule by inhibition radioimmunoassay (7) . In addition, noncapsulated mutants were passaged in vitro on BHI-N and screened for iridescence and capsule production by latex agglutination (10) . Briefly, 100 ml of each noncapsulated mutant was grown to 2 x 109 CFU/ml, harvested, and suspended in 1 ml of PBS, and 25 RI (5 x 109 CFU) was tested for capsule by latex agglutination. In addition, the noncapsulated mutants were recovered from mice and pigs, which were challenged and immunized with the mutants to determine whether reversion occurred in vivo. Virulence and immunoprotection. Pigs 6 to 8 weeks of age were obtained from a local commercial herd free of clinical pleuropneumonia. Sera from sows and piglets used in the study were assayed for antibodies to serotype 1 and 5 capsules by radioimmunoassay (7) and for antibodies to Apx toxins I and II by enzyme-linked immunosorbent assay (ELISA) (13) . All pigs used in this study had antibody titers for these antigens less than or within the negative range (7, 13 challenged intranasally or intratracheally 24 h after infection. However, A. pleuropneumoniae was recovered from the lungs of one pig challenged intranasally with J45-C, and the mutant was still noncapsulated ( Table 1) . None of the mutants recovered from immunizations of the pigs ever reverted to the encapsulated form, even though 4+ growth was usually recovered from the immunization sites. In addition, microporous capsules containing J45-C were implanted subcutaneously in pigs and recovered after 6 weeks; the cultured bacteria were still viable, and there was no evidence of any reversion to the encapsulated phenotype, as determined by iridescence and inhibition radioimmunoassay of pooled colonies (Table 2) .
Virulence and immunoprotection. Noncapsulated mutant J45-C was avirulent and caused no mortality in 10 pigs by intranasal exposure or intratracheal injection at a dose 20 or 10 times greater, respectively, than the LD50 of the parent.
The three pigs challenged intratracheally were necropsied 5 days postchallenge; all the pigs' lungs were healthy, and A. pleuropneumoniae was not recovered. The pigs challenged intranasally were necropsied 1, 3, and 7 days postchallenge; only one pig examined 7 days after intranasal challenge had pneumonia (about 35% of the total lung mass), but the bacteria recovered were still noncapsulated. In all other pigs challenged intranasally, the bacteria could not be recovered from the lungs, even 24 h after challenge (Table 1) . However, the bacteria were capable of surviving for at least 2 to 3 weeks subcutaneously or intradermally in PBS, Freund's incomplete adjuvant, 7% mucin, or agarose beads (Table 2) . Intradermal immunizations resulted in more severe inflammation and necrosis at the injection site than occurred with subcutaneous immunizations.
The strongest immune response to the Apx toxins and the greatest protection against challenge occurred when the pigs were immunized subcutaneously with J45-C in PBS or Freund's incomplete adjuvant ( Table 2 e Of seven pigs immunized intranasally, bacteria were recovered from the lungs of one pig 7 days after immunization (same pig as in Table 1 ) but not from the lungs or trachea of any pigs 1 or 3 days after immunization. (Tables 3 and 4 ). In contrast, antibody titers to capsule remained in the negative range for pigs immunized with the mutants but were positive in pigs immunized with the parents (Table 4) . DISCUSSION Current A. pleuropneumoniae killed vaccines are known to be inadequate, particularly against the development of lesions and chronic infections (5, 16, 18) . Killed vaccines, though lacking extracellular Apx toxins, do provide some protective immunity, indicating that somatic antigens may also contribute to protection. In contrast, previous infection with a virulent strain is thought to provide optimal protection against reinfection by any serotype (17) . Recent evidence has shown that antibodies to one or more of the Apx toxins of A. pleuropneumoniae may confer greater protection on pigs than do other specific antigens that have been examined (2, 3, 11 We chose a severe, intratracheal challenge that kills or causes acute lesions of pleuropneumonia in all nonimmune pigs challenged in order to test the limits of the protective efficacy of these mutants and to ensure that all challenges were identical in dose and reproducible. All the pigs immunized twice with 2 x 109 CFU of either attenuated serotype in PBS were significantly protected against challenge. In contrast, pigs immunized with a commercial bacterin were protected no better than control pigs against the challenge dose administered (100% mortality for both groups). The noncapsulated mutants reported here have several advantages that make them ideal live-vaccine candidates. (i) They are highly efficacious and appear to provide protection similar to that induced by the parent against homologous and heterologous serotype challenge. (ii) They are safe and cannot persist or cause substantial infection in the lung; the release of recombinant, mutagenic agents into the environment is not a factor. (iii) They are extremely stable and have never reverted to the encapsulated phenotype in vivo or in vitro. (iv) They do not induce antibodies to capsule, and immunized pigs can therefore be distinguished from infected pigs. (v) They can replicate and induce a protective immune response when administered subcutaneously without any adjuvant; therefore, inconvenient and expensive aerosol or intranasal immunization is not required, and lesions or side effects due to adjuvants do not occur. (vi) A commercial preparation of this type of vaccine would be less costly than current killed vaccines, making it economically feasible. An eightfold or greater rise in titer to the Apx toxins by ELISA after immunization was a good indicator that the pigs would be protected against challenge. Therefore, an ELISA for antibody to the Apx toxins may be useful in predicting protective immunity in individuals or in a herd.
Encapsulated bacteria that cause disease in their host primarily by the release of extracellular toxins are relatively common, particularly in veterinary medicine (e.g., Pasteurella haemolytica). Since such toxins are highly labile and difficult to purify, like A. pleuropneumoniae, live noncapsulated mutants of toxin-producing bacteria may prove to be highly efficacious vaccine candidates.
